Limits...
Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib.

Valpione S, Campana LG, Pigozzo J, Chiarion-Sileni V - Radiol Oncol (2015)

Bottom Line: Small molecules that inhibit V600 mutated BRAF protein, such as vemurafenib and dabrafenib, are effective in treatment of metastatic melanoma.We here describe the clinical course of a V600E BRAF mutated metastatic melanoma patient with systemic disease, who developed tumor progression on superficial soft-tissue metastases during treatment with dabrafenib.The new combined approach maintained the patient quality of life and allowed for the prosecution of the target therapy, which proved to be still effective on systemic disease, up to 17 months.

View Article: PubMed Central - PubMed

Affiliation: Melanoma Oncology Unit, Veneto Region Oncology Research Institute (IOV-IRCCS), Padova, Italy.

ABSTRACT

Background: Small molecules that inhibit V600 mutated BRAF protein, such as vemurafenib and dabrafenib, are effective in treatment of metastatic melanoma.

Case report: We here describe the clinical course of a V600E BRAF mutated metastatic melanoma patient with systemic disease, who developed tumor progression on superficial soft-tissue metastases during treatment with dabrafenib. Bleomycin electrochemotherapy during dabrafenib treatment was administered to control the soft-tissue progressing metastases and ensured sustained local control without significant toxicity.

Conclusions: The new combined approach maintained the patient quality of life and allowed for the prosecution of the target therapy, which proved to be still effective on systemic disease, up to 17 months.

No MeSH data available.


Related in: MedlinePlus

Clinical course of a metastatic melanoma patient initially treated with dabrafenib and subsequently temozolomide, combined with electrochemotherapy on superficial tumor nodules.In July 2013 the patient had multiple nodal and soft tissue metastases; (A) in October 2012 the left thigh of the patient was covered with white spots in the site of the metastases responsive to dabrafenib (white dotted arrows); at that time, only two bulging nodules were appreciable (black arrows); (B) despite the good response to dabrafenib on visceral metastases, in January 2013 three of these lesions worsened and one was ulcerated (black arrows); (C) in June 2013, after the first ECT course the metastases of the left thigh shrank; (D) in November 2013, new multiple skin metastases developed. Nevertheless, tumor control at the site of initial metastases that were responsive to dabrafenib and ECT was maintained (white arrows).Jagged arrows symbolize ECT courses.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4362609&req=5

f2-rado-49-01-71: Clinical course of a metastatic melanoma patient initially treated with dabrafenib and subsequently temozolomide, combined with electrochemotherapy on superficial tumor nodules.In July 2013 the patient had multiple nodal and soft tissue metastases; (A) in October 2012 the left thigh of the patient was covered with white spots in the site of the metastases responsive to dabrafenib (white dotted arrows); at that time, only two bulging nodules were appreciable (black arrows); (B) despite the good response to dabrafenib on visceral metastases, in January 2013 three of these lesions worsened and one was ulcerated (black arrows); (C) in June 2013, after the first ECT course the metastases of the left thigh shrank; (D) in November 2013, new multiple skin metastases developed. Nevertheless, tumor control at the site of initial metastases that were responsive to dabrafenib and ECT was maintained (white arrows).Jagged arrows symbolize ECT courses.

Mentions: In January 2013, the majority of subcutaneous lesions were stable except three, which progressively increased becoming symptomatic (Figure 2A and 2B).


Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib.

Valpione S, Campana LG, Pigozzo J, Chiarion-Sileni V - Radiol Oncol (2015)

Clinical course of a metastatic melanoma patient initially treated with dabrafenib and subsequently temozolomide, combined with electrochemotherapy on superficial tumor nodules.In July 2013 the patient had multiple nodal and soft tissue metastases; (A) in October 2012 the left thigh of the patient was covered with white spots in the site of the metastases responsive to dabrafenib (white dotted arrows); at that time, only two bulging nodules were appreciable (black arrows); (B) despite the good response to dabrafenib on visceral metastases, in January 2013 three of these lesions worsened and one was ulcerated (black arrows); (C) in June 2013, after the first ECT course the metastases of the left thigh shrank; (D) in November 2013, new multiple skin metastases developed. Nevertheless, tumor control at the site of initial metastases that were responsive to dabrafenib and ECT was maintained (white arrows).Jagged arrows symbolize ECT courses.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4362609&req=5

f2-rado-49-01-71: Clinical course of a metastatic melanoma patient initially treated with dabrafenib and subsequently temozolomide, combined with electrochemotherapy on superficial tumor nodules.In July 2013 the patient had multiple nodal and soft tissue metastases; (A) in October 2012 the left thigh of the patient was covered with white spots in the site of the metastases responsive to dabrafenib (white dotted arrows); at that time, only two bulging nodules were appreciable (black arrows); (B) despite the good response to dabrafenib on visceral metastases, in January 2013 three of these lesions worsened and one was ulcerated (black arrows); (C) in June 2013, after the first ECT course the metastases of the left thigh shrank; (D) in November 2013, new multiple skin metastases developed. Nevertheless, tumor control at the site of initial metastases that were responsive to dabrafenib and ECT was maintained (white arrows).Jagged arrows symbolize ECT courses.
Mentions: In January 2013, the majority of subcutaneous lesions were stable except three, which progressively increased becoming symptomatic (Figure 2A and 2B).

Bottom Line: Small molecules that inhibit V600 mutated BRAF protein, such as vemurafenib and dabrafenib, are effective in treatment of metastatic melanoma.We here describe the clinical course of a V600E BRAF mutated metastatic melanoma patient with systemic disease, who developed tumor progression on superficial soft-tissue metastases during treatment with dabrafenib.The new combined approach maintained the patient quality of life and allowed for the prosecution of the target therapy, which proved to be still effective on systemic disease, up to 17 months.

View Article: PubMed Central - PubMed

Affiliation: Melanoma Oncology Unit, Veneto Region Oncology Research Institute (IOV-IRCCS), Padova, Italy.

ABSTRACT

Background: Small molecules that inhibit V600 mutated BRAF protein, such as vemurafenib and dabrafenib, are effective in treatment of metastatic melanoma.

Case report: We here describe the clinical course of a V600E BRAF mutated metastatic melanoma patient with systemic disease, who developed tumor progression on superficial soft-tissue metastases during treatment with dabrafenib. Bleomycin electrochemotherapy during dabrafenib treatment was administered to control the soft-tissue progressing metastases and ensured sustained local control without significant toxicity.

Conclusions: The new combined approach maintained the patient quality of life and allowed for the prosecution of the target therapy, which proved to be still effective on systemic disease, up to 17 months.

No MeSH data available.


Related in: MedlinePlus